Twist Bioscience Corp — Director's Dealing 2020

Dec 9, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2020-12-07

Reporting Person: CRANDELL KEITH (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-08-18	Common Stock	J	685613	—	Disposed	1721809	Indirect
2020-08-18	Common Stock	J	34845	—	Acquired	34845	Indirect
2020-08-18	Common Stock	J	248083	—	Disposed	706063	Indirect
2020-08-18	Common Stock	J	3	—	Acquired	34848	Indirect
2020-09-02	Common Stock	J	497032	—	Disposed	1224777	Indirect
2020-09-02	Common Stock	J	25261	—	Acquired	60109	Indirect
2020-09-02	Common Stock	J	220641	—	Disposed	485422	Indirect
2020-09-02	Common Stock	J	3	—	Acquired	60112	Indirect
2020-09-15	Common Stock	J	444231	—	Disposed	780546	Indirect
2020-09-15	Common Stock	J	22578	—	Acquired	82690	Indirect
2020-09-15	Common Stock	J	176030	—	Disposed	309392	Indirect
2020-09-15	Common Stock	J	2	—	Acquired	82692	Indirect
2020-12-07	Common Stock	S	53712	$103.40	Disposed	726834	Indirect
2020-12-07	Common Stock	S	21288	$103.40	Disposed	288104	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1412	Direct

Footnotes

F1: Pro-rata distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2: The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("AVP GPLLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: Keith Crandell is a managing director of ARCH VII LLC and ARCH VIII LLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F5: Change in form of ownership of shares previously reported as beneficially owned by the reporting person.